baber/WOPTO huggingface dataset:
Patent DK-1827295-T3 (DK)
Inventor: BERTRAM-JACOBSEN THEIS
IPC: A61C5/00
Filed: 2005-12-13
Granted: 2009-05-18
Abstract: A dental insertion for a tooth filling, the insertion having a surface and a body extending from the surface, wherein at least one cavity is arranged in the surface, the cavity extending at least from the surface to a center of the body. Further, a dental insertion dummy having similar dimensions to a dental insertion, a device for handling of a dental insertion, a device of an electromagnetic radiation-conducting material for insertion into a dental insertion, a method for incorporating a dental insertion for a tooth filling into an interproximal space, a system including one or more of the insertions and devices and a method for production of insertions for dental treatment.
Patent DK-1812581-T3 (DK)
Inventor: ARGADE ANKUSH
IPC: C12P41/00
Filed: 2005-11-15
Granted: 2009-05-11
Abstract: The present disclosure provides enzymatic methods for generating stereoisomerically pure products by resolving a racemic mixture of N-protected beta-lactams with a lipase from Candida antarctica with high stereospecificity. The presence of a carbamate protecting group, such as the tert-butoxycarbonyl group protecting group, on the beta-lactam enhances enzyme catalysis and stereoselectivity.
Patent DK-1715340-T3 (DK)
Inventor: LEIGHTON STEPHEN B
IPC: G01N33/566
Filed: 1999-02-24
Granted: 2009-01-26
Abstract: An array-based technology facilitates rapid correlated gene copy number and expression profiling of a very large numbers of human tumors. Hundreds of cylindrical tissue biopsies (diameter 0.6 mm) from morphologically representative regions of individual tumors can be arrayed in a single paraffin block. Consecutive sections from such arrays provide targets for parallel in situ visualization and quantitation of DNA, RNA or protein targets. For example, amplifications of six loci (mybL2, erbB2, Cyelin-D1, riryc, 17q23 and 20q13) were rapidly determined by fluorescence in situ hybridization from 372 ethanol-fixed breast cancers. Stratifcation of tumors by estrogen receptor and p53 expression data revealed distinct patterns of gene amplification in the various subgroups of breast cancer that may have prognostic utility. The tissue array technology is useful in the rapid molecular profiling of hundreds of normal and pathological tissue specimens or cultured cells.
Patent DK-1875239-T3 (DK)
Inventor: KOLB HARTMUTH C
IPC: G01N33/532
Filed: 2006-04-27
Granted: 2012-01-23
Abstract: The invention provides a method for identifying a candidate imaging probe, the method comprising: a) contacting a first library of candidate compounds with a target biomacromolecule, b) identifying a first member from the first library exhibiting affinity for the first binding site; c) contacting the first member identified from the first library affinity for the first binding site with the target biomacromolecule; d) contacting a second library of candidate compounds with the first member and the target biomacromolecule, e) reacting the complementary first functional group with the second functional group via a biomacromolecule induced click chemistry reaction to form the candidate imaging probe; f) isolating and identifying the candidate imaging probe; g) preparing the candidate imaging probe by chemical synthesis; and h) for imaging applications, converting the candidate imaging probe into an imaging probe.
Patent DK-1910198-T3 (DK)
Inventor: PARKINSON DAVID JOHN
IPC: B65G53/22
Filed: 2006-08-02
Granted: 2011-01-10
Abstract: A fluidizing apparatus comprises a vessel having an inlet, a plurality of outlets and a nozzle, through which a pressurized fluid can be fed into the vessel. The outlets are spaced at different heights from a base of the vessel and are controlled by valves enabling fluidized solids to be removed in layers from the vessel. In a further embodiment, a single outlet is raised or lowered to a desired position in the vessel.
Patent DK-1919874-T3 (DK)
Inventor: TORISAWA YASUHIRO
IPC: C07D223/16
Filed: 2006-09-01
Granted: 2011-02-21
Abstract: This invention provides a process for preparing benzazepine compounds of the formula (1):   
wherein X 1  is a halogen atom, R 1  and R 2  are a lower alkyl group, or salts thereof as well as intermediate benzoic acid compounds in high yield and high purity on industrial scale, which are useful as an intermediate for preparing a pharmaceutically active 2,3,4,5-tetrahydro-1H-1-benzazepine compound having vasopressin antagonistic activity.
Patent DK-2013284-T3 (DK)
Inventor: ABUSLEME JULIO
IPC: C08L27/12
Filed: 2007-04-23
Granted: 2010-01-04
Abstract: This invention pertains to a thermoplastic fluoropolymer composition comprising : 
- at least one thermoplastic hydrogen-containing fluoropolymer [polymer (A)]; and 
- from 0.1 to 10 % by weight of (A) of at least one per(halo)fluoropolymer chosen among tetrafluoroethylene (TFE) copolymers having a dynamic viscosity at a shear rate of 1 rad × sec -1  of less than 10 Pa × sec at a temperature of 280°C [polymer (B)].  The addition of a TFE copolymer [polymer (B)] of low melt viscosity advantageously enables improvement of rheological behavior of thermoplastic hydrogen-containing fluoropolymer (A), making possible processing in less severe conditions and yielding final parts with outstanding surface aspect and good homogeneity and coherency.  Still objects of the invention are a process for manufacturing said thermoplastic fluoropolymer composition and the articles, such as shaped articles, films, cable sheathing, pipes, flexible pipes, hollow bodies comprising said thermoplastic fluoropolymer composition.
Patent DK-2066523-T3 (DK)
Inventor: CAPACCHIONE RENATO
IPC: B60M1/26
Filed: 2007-09-19
Granted: 2011-09-26
Abstract: A device for compensating variations in the length of tensioned cables, with substantially constant tension, comprising a contrast element (2, 2a) which is designed to be interposed between one end of the tensioned cable (3) and an anchoring element and is adapted to generate an elastic reaction which can vary as a function of the length variation of the cable (3), the device comprising connection means (4, 4a) for connecting the contrast element (2, 2a) to the cable (3), which are adapted to convert the elastic reaction of the contrast element (2, 2a) into a substantially constant tension applied to the cable (3), regardless of its length, over a preset length variation range, the contrast element being constituted by at least one spiral spring (5, 5a) and the connection means being preferably constituted by at least one variable-radius pulley (6, 6a), which is connected to the spiral spring (5, 5a) and is provided with at least one winding race (11, 11a) for the cable (3) to be tensioned or for a wire-like element (8, 8a) connected to the cable (3) to be tensioned.
Patent DK-1978391-T3 (DK)
Inventor: LE NOANE GEORGES
IPC: G02B6/44
Filed: 2001-06-18
Granted: 2010-08-09
Abstract: The optical cable (1) comprises a closed protective sheath (6) which is preferably oval in cross-section. Optical fibres (3), optionally assembled in modules (2), are arranged so that they take up the major part of the cavity in one axis, but allow significant clearance in other axis of the cavity. This allows branch connections from the cable outer sheath. The optical cable (1) comprises a closed protective sheath (6) which is preferably oval in cross-section, enclosing a cavity (5). The two perpendicular axes of the oval intersect at the center of gravity. At least two optical fibres (3), optionally assembled in modules (2), are arranged so that they take up the major part of the cavity in one axis, but allow significant clearance in other axis of the cavity. The fibres are preferably arranged along the longitudinal axis. The cable is continuously accessible as a result of its oval shape. One axis provides for easy curvature and accessibility to modules distributed along the large dimension, whilst the other axis provides significant clearance between the modules, facilitating extraction and providing the cable with good thermal and mechanical properties.
Patent DK-2215480-T3 (DK)
Inventor: VINK HANS
IPC: G01N33/68
Filed: 2008-12-01
Granted: 2012-07-30
Abstract: The invention relates to diagnostic and therapeutic tools and applications, particularly useful in diseases that affect vascular health and in inflammatory diseases. In particular, said diagnostic and therapeutic tools employ suitable detection or modulation of endothelial glycocalyx.
Patent DK-2249963-T3 (DK)
Inventor: DUBREUIL ANNE-CLAIRE
IPC: C01F7/441
Filed: 2009-01-30
Granted: 2012-01-16
Abstract: The invention concerns a catalyst comprising nickel on an aluminum oxide support. The aluminum oxide support has, in the calcined state, a diffractogram obtained by X ray diffractometry comprising peaks which correspond to the following interplanar spacings and relative intensities: Interplanar spacings Relative intensities d (10-10 m ) I/I0 (%) 5.03 to 5.22 1-5 4.56 to 4.60 1-10 4.06 to 4.10 1-5 2.80 to 2.85 5-20 2.73 15-35 2.60 5-10 2.43 35-40 2.29 30-40 1.99 60-95 1.95 25-50 1.79 1-10 1.53 5-10 1.51 5-10 1.41 40-60 1.39 100 1.23 to 1.26 1-5 1.14 5-10 1.11 1-5 1.04 1-5 1.00 5-10 0.97 1-5.
Patent DK-2223687-T3 (DK)
Inventor: MAN HON-WAH
IPC: C07D209/48
Filed: 2003-03-20
Granted: 2017-08-14
Abstract: Discussed is stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable polymorph, salt, solvate or hydrate thereof, as well as a pharmaceutical composition or single unit dosage form comprising such compound and such compound for use as a medicine.
Patent DK-3189696-T3 (DK)
Inventor: LANGEREIS ALEXANDER
IPC: H04W56/00
Filed: 2014-09-02
Granted: 2018-08-13
Abstract: A method of operation of a base station in a cellular communications network, in which user equipment devices in a cell served by the base station need to be synchronized with the cell on the uplink in order to transmit data, and in which Radio Resource Control, RRC, connected user equipment devices can be kept synchronized with the cell on the uplink or not synchronized. The method comprises making a determination as to whether a specified condition within the cell served by the base station is fulfilled, and, in response to the determination as to whether the specified condition within the cell is fulfilled, determining whether RRC connected user equipment devices should be kept uplink synchronized with the cell, or whether RRC connected user equipment devices should be allowed to become not synchronized on the uplink. Signals are transmitted to user equipment devices to affect whether or not the RRC connected user equipment devices are kept uplink synchronized with the cell, in response to determining whether RRC connected user equipment devices should be kept uplink synchronized with the cell, or whether RRC connected user equipment devices should be allowed to become not synchronized on the uplink.
Patent DK-0445403-T3 (DK)
Inventor: SCHMIDT HANS JOACHIM
IPC: B26D7/32
Filed: 1990-12-18
Granted: 1994-10-05
Abstract: A device for sectioning cut product, preferably pieces of meat, in particular sides of salmon, into slices has a cutting station and a conveyor device (2) guiding the cut product through the cutting station. The conveyor device (2) comprises a track member (3) whose support surface (4) for the cut product comprises track sections (15, 16) arranged adjacent to each other, a predetermined number of track sections (16) being designed as entraining devices for the cut product which can be moved by steps, relative to adjacent track sections (15), by means of a drive member. 
<??>The drive member comprises elements for a vertical drive (18) and for a horizontal drive (20) of the movable track sections (16). Each track section (15) is a strip extending over the length of the track member (3). 
<IMAGE>
Patent DK-0470192-T3 (DK)
Inventor: COLE FRANCIS X
IPC: G01N33/535
Filed: 1990-04-16
Granted: 1997-10-27
Abstract: A lyophilized mixture of reactants for an immunoassay includes antibody-gold sol particle conjugates, antibody latex particle conjugates, polyethylene glycol, a polyethylene glycol p-isooctylphenyl ether detergent and a sugar such as dextrin or trehalose. The polyethylene glycol is present to enhance binding of the immunoreactants and the polyethylene glycol p-isooctylphenyl ether detergent is present to prevent non-specific interactions. The sugar prevents agglomeration of the polyethylene glycol and polyethylene glycol p-isooctylphenyl ether in the lyophilized mixture at room temperature and facilitates retention of a homogenous distribution of the ingredients of the mixture to thereby enhance shelf life and redistribution of the mixture in an aqueous test system.
Patent DK-0478715-T3 (DK)
Inventor: CULLIS PIETER R
IPC: A61K47/42
Filed: 1990-06-22
Granted: 1996-08-05
Abstract: This invention relates to a method for synthesizing a substantially pure reactive lipid including, for example, N-[4-(p-maleimidophenyl)-butyryl]phosphatidylethanolamine (MPB-PE) and related compositions. The compositions of the present invention are useful as coupling agents and may be incorporated into liposomes and subseuquently coupled to proteins, cofactors and a number of other molecules. A preferred coupling method is also disclosed as are protein conjugates. The present invention also relates to a general method for producing sized protein-liposome conjugates exhibiting enhanced blood circulation times. The present invention also relates to the sized protein-liposome conjugate compositions produced by the method of the present invention. The protein-liposome conjugates of the present invention preferably range in size from about 75 nm to about 200 nm. The liposomes of the invention may have a trans-membrane potential across their membranes, and may be dehydrated. In addition, the composition may contain ionizable bioactive agents such as antineoplastic agents, and may be used in diagnostic assays.
Patent DK-0488702-T3 (DK)
Inventor: SPANGLER MICHAEL
IPC: B65G17/00
Filed: 1991-11-28
Granted: 1997-05-12
Abstract: A spiral conveyor system utilising an endless flat belt (12) is disclosed. The belt (12) travels in an endless path which includes a spiral portion. The belt (12) is primarily driven in the spiral portion by a frictional engagement between the belt (12) and a rotating driving element (26). The frictional engagement is enhanced by attaching friction increasing elements (40) to the belt (12) and/or driving element (26). <IMAGE>   <IMAGE>
Patent DK-0473527-T3 (DK)
Inventor: IBANEZ PALOMEQUE FRANCISCO
IPC: H04M17/02
Filed: 1991-07-25
Granted: 1995-07-17
Abstract: Such comprising the software included in the system in order to carry out the necessary transactions to validate credit cards used in modular public telephones, communicating with the modular public telephone validation and identification unit, and capable of managing the invoicing of such calls in respect of each of the credit organisations involved, allowing a standard protocol to be adapted for communication with the management centres of credit organisations and with the management centre of the telephone company in accordance with a set message structure. <IMAGE>
Patent DK-0534640-T3 (DK)
Inventor: BANKER MICHAEL J
IPC: C12Q1/68
Filed: 1992-09-09
Granted: 1997-03-17
Abstract: This invention relates to a process for detecting the presence and measuring the quantity of specific mRNA sequences present in in vivo cells or cells maintained in vitro. The process of this invention is applicable to the screening of procaryotic and eucaryotic organisms including the screening of human beings for the presence of disease states. The process of this invention is also applicable to the in vitro screening of the effect or effects of chemical compounds upon one or several gene products as exhibited by the presence and amount of mRNA resulting from transcription of said gene or genes. The process of this invention is particularly suited for screening of a large number of compounds for the effect or effects of compounds upon gene products. This invention also relates to compounds capable of affecting the presence of specific mRNA sequences in cells. The process of this invention also is applicable to the identification of novel gene constructs in viruses, microorganisms, plants and animals. This invention also relates to a novel process for the isolation of RNA and DNA from cells, by lysing them in water heated to about 99 DEG C.
Patent DK-0526302-T3 (DK)
Inventor: NGUYEN QUANG LAN
IPC: A61K8/00
Filed: 1992-07-17
Granted: 1995-04-24
Abstract: Use of (2,5-dihydroxyphenyl)carboxylic acid derivatives, their homologues and their salts for the preparation of a cosmetic or dermatological composition having a depigmenting action, characterised in that the said derivatives correspond to the following formula: <IMAGE>  in which:     R1 represents OR5, OH or <IMAGE> R5 represents a linear or branched C1-C20 alkyl radical, a linear r branched C2-C20 alkenyl radical or a C1-C20 alkyl radical substituted by one or a number of hydroxyl or alkoxy groups, r' and r'', which are identical or different, represent a hydrogen atom, a C1-C20 alkyl radical, a C2-C6 hydroxyalkyl radical or a C3-C6 polyhydroxyalkyl radical or r' and r'' taken together, with the nitrogen atom, form a heterocycle, the number of carbon atoms of the chain -(CH2)n-COR1 being less than or equal to 21, R2 and R3, which are identical or different, represent a hydrogen atom, a linear or branched C1-C4 alkyl radical or a C1-C4 alkoxy, R4 represents a hydrogen atom or a linear or branched C1-C4 alkyl radical, and n is 0 to 20, with the proviso that when R2 and R3 represent a hydrogen atom, n is greater than or equal to 2.
Patent DK-0549742-T3 (DK)
Inventor: LOGOTHETOU-RELLA HELEN
IPC: A61P31/12
Filed: 1992-06-02
Granted: 2004-07-26
Abstract: The invention relates to the use of inhibitors of neutral Ca<2+> dependent proteinases (CANPs) and their pharmaceutically acceptable addition salts or their active subunits in the field of tumour therapy, especially cancer therapy, viral diseases therapy, AIDS therapy and contraception. The inhibitors can especially be used against protease bound glycosaminoglycan-substrate dependent tumours, viral diseases and contraception by selective malignant cell killing, viruses and spermatozoa killing and inhibiting of nuclear vlimmata in a host-parasite cell system involving common protease bound substrate. The inhibitors are heatstable, tetrameric proteins at neutral pH, approximatively 240 KDa, destroyed with trypsin. The pharmaceutical compositions may be prepared in a manner known per se, with carriers or additives commonly used in the pharmaceutical industry.
Patent DK-0588926-T3 (DK)
Inventor: RANCOURT CLAUDE
IPC: F16D69/00
Filed: 1992-06-22
Granted: 1999-06-23
Abstract: An improved truck disc brake using a spring loaded safety brake and a pneumatic bladder (68) for releasing the safety brake as well as a service brake enhancing bladder (70) and a pair of rotor brake discs (22, 24). The brake discs (22, 24) are ventilated and include ventilation channels (46) extending radially thereof and vent air is deflected into the brake assembly by means of a scoop (134) on the exterior of the housing (18) passing through openings (148) in the housing and the rotor brake discs (22, 24) act as an impeller moving the ventilation air outwardly thereof to dissipate the heat. A wear gauge (110, 112, 132) is provided to determine the wear of the brake linings (52, 56, 58) and discs (22, 24) and a quick release valve (126) is mounted in the brake assembly adjacent the pneumatic bladder (70) related to the service brake, to quickly release the air when required. Temperature sensors (100, 102) are provided within the brake assembly to read the temperature of the brake assembly. A radial groove (142) extends on the friction surface of the radial disc to provide an air cushion between the brake linings (52, 56, 58) and the friction surface (22a, 22b, 24a, 24b) of the disc (22, 24) and to discharge debris.  <IMAGE>
Patent DK-0624152-T3 (DK)
Inventor: QUALLICH GEORGE J
IPC: C07F7/18
Filed: 1992-09-15
Granted: 1996-12-30
Abstract: A novel multi-step process for preparing the (4S &cir& _-enantiomer of 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenone in a highly-optically pure form is disclosed. The process involves (1) first esterifying 4-(3,4-dichlorophenyl)-4-ketobutanoic acid with isopropylene or isobutylene to form the corresponding isopropyl or t &cir& _e &cir& _r &cir& _t &cir& _.-butyl 4-(3,4-dichlorophenyl)-4-ketobutanoate; (2) then reducing the ketobutanoic acid ester obtained in the first step with an asymmetric carbonyl reducing agent to form the corresponding chiral isopropyl or t &cir& _e &cir& _r &cir& _t &cir& _.-butyl 4-(3,4-dichlorophenyl)-(4R &cir& _)-hydroxybutanoate; (3) then sulfonylating the (4R &cir& _)-hydroxybutanoic acid ester with methanesulfonyl, benzenesulfonyl or p &cir& _-toluenesulfonyl chloride or bromide in the presence of a standard base to yield the corresponding isopropyl or t &cir& _e &cir& _r &cir& _t &cir& _.-butyl 4-(3,4-dichlorophenyl)-(4R &cir& _)-sulfonyloxybutanoate; (4) next subjecting the 4-sulfonyloxybutanoic acid ester obtained in the third step to a copper-coupling reaction with dilithium diphenyl(cyano)cuprate of the formula  PHI 2Cu(CN)Li2 to effect a stereochemical displacement of the organic (4R &cir& _)-sulfonyloxy group of the (4R &cir& _)-sulfonyloxybutanoic acid ester by the phenyl group of the dilithium diphenylcuprate reagent and so selectively form the corresponding isopropyl or t &cir& _e &cir& _r &cir& _t &cir& _.-butyl 4-(3,4-dichlorophenyl)-(4R &cir& _)-phenylbutanoate, and (5) thereafter cyclizing the stereospecific (4R &cir& _)-phenylated n-butanoic acid ester in the presence of a protic or Lewis acid catalyst to finally yield the desired (4S &cir& _)-4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenone compound in a highly-optically pure form. The latter compound, which is a novel (4S &cir& _)-enantiomer per se, has utility as an intermediate that ultimately leads to pure c &cir& _i &cir& _s &cir& _-(1S &cir& _)(4S &cir& _)N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthaleneamine (sertraline), which is a known antidepressant agent. The aforementioned isopropyl and t &cir& _e &cir& _r &cir& _t &cir& _.-butyl esters of 4-(3,4-dichlorophenyl)-(4R &cir& _)-hydroxybutanoic acid, as well as their corresponding (4R &cir& _)-methanesulfonyl, (4R &cir& _)-benzenesulfonyl and (4R &cir& _)-p &cir& _-toluenesulfonyl derivatives, are also novel compounds, as are the aforementioned isopropyl and t &cir& _e &cir& _r &cir& _t &cir& _.-butyl esters of 4-(3,4-dichlorophenyl)-(4R &cir& _)-phenylbutanoic acid as well as the aforesaid acid per se. These novel chiral compounds are all useful as key intermediates in the overall process of the present invention.
Patent DK-0565665-T3 (DK)
Inventor: HAWKINS PAMELA L
IPC: C07K14/745
Filed: 1992-09-25
Granted: 1998-09-28
Abstract: A prothrombin time reagent is disclosed for use in a prothrombin time test. The reagent utilizes recombinant human tissue factor, phospholipids of a natural or synthetic origin, a buffer composition and calcium ion. Stabilizers and salts may also be utilized in the reagent. In addition, a method for creating lipid micelles containing tissue factor is also disclosed.